|Day's range||0.8000 - 0.8000|
PARSIPPANY, N.J., May 30, 2023--Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2023 Jaws and Paws Conference on Wednesday, May 31, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:35 p.m. ET.
PARSIPPANY, N.J., May 25, 2023--Zoetis Inc. (NYSE:ZTS) is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D pipeline and its financial roadmap to continue delivering shareholder value, as it Shapes Animal Health for the Next Decade.
Microsoft, BP, Zoetis, Lululemon Athletica and Weyerhaeuser are part of the Zacks top Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), BP p.l.c. (BP) and Zoetis Inc. (ZTS).
PARSIPPANY, N.J., May 11, 2023--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.375 per share for the third quarter of 2023. The dividend will be paid on Friday, September 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Friday, July 21, 2023.
PARSIPPANY, N.J., May 05, 2023--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs. Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life. 1,2
For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and our SEC filings, including, but not limited to, our Annual Report on Form 10-K and our reports on Form 10-Q. Our remarks today will also include references to certain financial measures, which were not prepared in accordance with Generally Accepted Accounting Principles or U.S. GAAP. Meanwhile, our companion animal portfolio in the U.S. declined due to distributors destocking and reducing their inventories in the first quarter.
Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zoetis (ZTS) delivered earnings and revenue surprises of 3.15% and 0.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PARSIPPANY, N.J., May 04, 2023--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the first quarter of 2023 and maintained its guidance for full year 2023.
Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 210% and 9.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PARSIPPANY, N.J., May 01, 2023--Zoetis Inc. (NYSE:ZTS) will host an Investor Day on Thursday, May 25, 2023, at the New York Stock Exchange featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Chief Financial Officer; Robert Polzer, Ph.D., President of Research and Development; and other members of the Zoetis executive team. Zoetis will provide an update on the company’s strategy to deliver long-term profitable growth and value for shareholders, followed by a Q&A session.
Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.
The number of businesses led by women is growing every year. And as the results show, investors should embrace -- and invest in -- women-led companies.
Over the past decade, spending on veterinary care has tripled in the United States. The growth in that spending makes veterinary care stocks somewhat recession proof. More and more, spending on pet healthcare is seen as something people need rather than want.
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) closed the most recent trading day at $173.95, moving +0.58% from the previous trading session.
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Zoetis (ZTS) closed at $176.88, marking a +1.42% move from the previous day.
ALPMY vs. ZTS: Which Stock Is the Better Value Option?
NIKE, Toyota Motor, ConocoPhillips, PayPal and Zoetis are part of the Zacks top Analyst Blog.
Today's Research Daily features Q1 earnings season update and new research reports on NIKE, Inc. (NKE), Toyota (TM) and ConocoPhillips (COP).